Business Wire

Kinaxis Recognized as a Leader in TMS Technology by Nucleus Research

Share

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, has been named a Leader in the 2024 Transportation Management Technology Value Matrix by Nucleus Research, a renowned provider of ROI-focused technology research and advisory services. This recognition highlights Kinaxis’ commitment to pushing the boundaries of Transportation Management systems (TMS) with its AI-infused Maestro platform, helping businesses enhance agility, optimize operations and reduce costs across their supply chains.

The 2024 TMS Technology Value Matrix focuses on the solutions that deliver the highest value to organizations, assessing functionality and usability. Kinaxis stood out for its ability to move beyond traditional TMS functionality, integrating AI and machine learning to provide unparalleled real-time visibility, process automation, and intelligent decision-making across industries, including automotive, aerospace, life sciences and high tech.

“Kinaxis continues to invest and improve the capabilities of its transportation management platform,” said Charles A. Brennan, analyst at Nucleus Research. “By providing end-to-end visibility and enabling organizations to make more informed, data-driven decisions, Kinaxis has solidified its position as a Leader in this year’s TMS Technology Value Matrix.”

Key areas marking Kinaxis as a leader in the TMS Technology Value Matrix 2024 include:

  • Real-time visibility and control: End-to-end real-time visibility from manufacturing to last-mile delivery enables businesses to monitor and adjust operations, enhance decision-making and reduce risk.
  • Comprehensive transportation management: Support for all modes of transportation–truck, rail, ocean, air and parcel–facilitates route optimization and streamlines orders across diverse manufacturing sites, distribution centers and sales channels.
  • Integration with multi-enterprise networks: Seamless integration with global carrier networks and systems like ERP, WMS, eCommerce and 3PLs offers a unified view of the supply chain, connecting all stakeholders and systems.
  • Cost optimization and control: Real-time cost optimization and invoice matching help businesses manage transportation costs while ensuring alignment with service-level agreements, enhancing financial transparency and reducing overhead.
  • Enhanced supply chain orchestration: Expanded capabilities including order management, logistics control tower and multi-enterprise visibility, facilitate concurrent planning and execution.
  • Event management and exception handling: Real-time alerts and automated exception management for disruptions such as expedited orders, stock transfers or alternative supplier selection ensure rapid responses to supply chain challenges.
  • Innovative product updates: Continuous improvements to the Maestro platform include new APIs for inventory and available-to-promise data, enhanced user interface for ease of use and strengthened compliance measures for data integration and regulatory standards.

"As a leader in supply chain orchestration technology, our goal is to empower organizations with the tools they need to thrive in an increasingly complex landscape," said Andrew Bell, chief product officer at Kinaxis. "This recognition reflects our continued commitment to innovation and excellence, and solidifies Kinaxis as a transformative force, driving efficiency and cost savings for our customers.”

In an analysis of Maestro, published by Nucleus in July 2024, the analyst firm stated that it anticipates the AI-infused platform to deliver value to customers in the following areas: improved supply chain management, increased employee productivity, and enhanced supplier collaboration. Nucleus said it expects Maestro users to save approximately two to three hours daily by eliminating the need to compile data for reporting and analysis.

Click here to read the report in full.

To learn more about Kinaxis, please visit kinaxis.com.

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003351610/en/

Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
+1 289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com613-907-7613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai

HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release

Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa

Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release

TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi

SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release

On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye